Latest News
Zenas BioPharma, Inc.
- Morgan Stanley initiates Zenas Biopharma stock coverage with Equalweight rating
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease
- Zenas BioPharma presents extended obexelimab data for IgG4-RD
- Zenas BioPharma Announces the Presentation of New
- Zenas BioPharma to present MS drug data at MSToronto2026
- Zenas BioPharma to present MS research at Toronto conference By Investing.com
- Zenas BioPharma Announces Upcoming Presentations of
- Zenas BioPharma to Host Virtual R&D Event
- FDA accepts Zenas BioPharma's obexelimab with M...
- Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve (NASDAQ:ZBIO)
- Guggenheim reiterates Zenas Biopharma stock rating on IgG4-RD outlook
Headlines from the last 30 days, linking to the original publishers. See all market news →